Velox Biologics Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 23-10-2024
- Paid Up Capital ₹ 0.20 M
as on 23-10-2024
- Company Age 13 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 0.82 M
as on 23-10-2024
- Revenue 13.16%
(FY 2023)
- Profit -14.84%
(FY 2023)
- Ebitda 50.54%
(FY 2023)
- Net Worth 8.80%
(FY 2023)
- Total Assets -3.21%
(FY 2023)
About Velox Biologics
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.20 M.
The company currently has active open charges totaling ₹0.82 M.
Sumesh Sharma and Ashish Sharma serve as directors at the Company.
- CIN/LLPIN
U24232CH2011PTC032721
- Company No.
032721
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Feb 2011
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Velox Biologics Private Limited offer?
Velox Biologics Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Nutraceuticals & Dietary Supplements, Nutritional Supplements, Mineral Supplement, Antibiotic Tablets & Capsules, Cefixime Tablet, Ayurvedic Digestive Medicine, Digestive Enzyme Syrup, Allopathic Cough Syrup.
Who are the key members and board of directors at Velox Biologics?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashish Sharma  | Director | 28-Jan-2021 | Current |
| Sumesh Sharma | Director | 04-Feb-2011 | Current |
Financial Performance of Velox Biologics.
Velox Biologics Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.16% increase. The company also saw a substantial fall in profitability, with a 14.84% decrease in profit. The company's net worth moved up by a moderate rise of 8.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Velox Biologics?
In 2023, Velox Biologics had a promoter holding of 91.00% and a public holding of 9.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 06 Feb 2017 | ₹0.82 M | Open |
How Many Employees Work at Velox Biologics?
Unlock and access historical data on people associated with Velox Biologics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Velox Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Velox Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
